Get started
Author

Yasushi Tomii

Enhanced Inhibition of ERK Signaling by a Novel Allosteric MEK Inhibitor, CH5126766, That Suppresses Feedback Reactivation of RAF Activity
2013 · Nobuya Ishii, Naoki Harada, et al. · Cancer Research · 182
Antibody to CD137 Activated by Extracellular Adenosine Triphosphate Is Tumor Selective and Broadly Effective In Vivo without Systemic Immune Activation
2020 · Mika Kamata-Sakurai, Yoshinori Narita, et al. · Cancer Discovery · 104
Exploitation of Elevated Extracellular ATP to Specifically Direct Antibody to Tumor Microenvironment
2020 · Futa Mimoto, Kanako Tatsumi, et al. · Cell Reports · 75
PDF
Fluorine Scanning by Nonselective Fluorination: Enhancing Raf/MEK Inhibition while Keeping Physicochemical Properties
2013 · Ikumi Hyohdoh, Noriyuki Furuichi, et al. · ACS Medicinal Chemistry Letters · 41
Cell binding isoforms of vascular endothelial growth factor-A (VEGF189) contribute to blood flow-distant metastasis of pulmonary adenocarcinoma
2005 · Masatake Nishi, Yoshiyuki Abe, et al. · International Journal of Oncology · 35
Optimizing the Physicochemical Properties of Raf/MEK Inhibitors by Nitrogen Scanning
2014 · Toshihiro Aoki, Ikumi Hyohdoh, et al. · ACS Medicinal Chemistry Letters · 26
Interleukin 10 expression is correlated with thrombospondin expression and decreased vascular involvement in colon cancer
2001 · Tsutomu Kawakami, Tetsuji Tokunaga, et al. · International Journal of Oncology · 24
The sulfamide moiety affords higher inhibitory activity and oral bioavailability to a series of coumarin dual selective RAF/MEK inhibitors
2013 · Toshihiro Aoki, Ikumi Hyohdoh, et al. · Bioorganic & Medicinal Chemistry Letters · 22
Human thrombospondin 2 inhibits proliferation of microvascular endothelial cells
2002 · Yasushi Tomii, Junichiro Kamochi, et al. · International Journal of Oncology · 19
The modifier subunit of glutamate cysteine ligase (GCLM) is a molecular target for amelioration of cisplatin resistance in lung cancer
2003 · Yoshimasa Inoue, Masashi Tomisawa, et al. · International Journal of Oncology · 18
Unique properties of 189 amino acid isoform of vascular endothelial growth factor in tumorigenesis
2002 · Yasushi Tomii, Hitoshi Yamazaki, et al. · International Journal of Oncology · 16
Overexpression of the thrombospondin 2 (TSP2) gene modulated by the matrix metalloproteinase family expression and production in human colon carcinoma cell line
2003 · Junichiro Kamochi, Tetsuji Tokunaga, et al. · Oncology Reports · 14
Ribozyme mediated suppression of vascular endothelial growth factor gene expression enhances matrix metalloproteinase 1 expression in a human hepatocellular carcinoma cell line
2002 · Junichiro Kamochi, Tetsuji Tokunaga, et al. · International Journal of Oncology · 9
ROSE12, a novel anti-CTLA-4 FcγRs binding-enhanced antibody activated by extracellular adenosine triphosphate, shows tumor-selective regulatory T-cell depletion and antitumor efficacy without systemic immune activation
2026 · Hiroki Hayashi, Kanako Tatsumi, et al. · Journal for ImmunoTherapy of Cancer · 3
PDF
Abstract 2789: Discovery of a novel specific MEK and Raf inhibitor, CH5126766 (RO5126766), hit to lead study of a unique scaffold for kinase inhibitor to a clinical compound
2011 · Hitoshi Iikura, Toshihiro Aoki, et al. · Cancer Research · 1
Abstract 6063: ROSE12, a novel anti-CTLA-4 Switch antibody™ with FcγR affinity-enhanced Fc, evokes tumor-selective anti-tumor immune activation by extracellular ATP without systemic immune activation
2025 · Hiroki Hayashi, Kanako Tatsumi, et al. · Cancer Research
920 ROSE12, a novel anti-CTLA-4 switch antibody with FcγR affinity-enhanced Fc, evokes tumor-selective anti-tumor immune response, activated by extracellular ATP in tumor microenvironment
2024 · Hiroki Hayashi, Kanako Tatsumi, et al. · Journal for ImmunoTherapy of Cancer
Supplementary Data from Antibody to CD137 Activated by Extracellular Adenosine Triphosphate Is Tumor Selective and Broadly Effective In Vivo without Systemic Immune Activation
2023 · Mika Kamata-Sakurai, Yoshinori Narita, et al.
Data from Antibody to CD137 Activated by Extracellular Adenosine Triphosphate Is Tumor Selective and Broadly Effective In Vivo without Systemic Immune Activation
2023 · Mika Kamata-Sakurai, Yoshinori Narita, et al.
Supplementary Data from Antibody to CD137 Activated by Extracellular Adenosine Triphosphate Is Tumor Selective and Broadly Effective In Vivo without Systemic Immune Activation
2023 · Mika Kamata-Sakurai, Yoshinori Narita, et al.
Data from Antibody to CD137 Activated by Extracellular Adenosine Triphosphate Is Tumor Selective and Broadly Effective In Vivo without Systemic Immune Activation
2023 · Mika Kamata-Sakurai, Yoshinori Narita, et al.
Data from Enhanced Inhibition of ERK Signaling by a Novel Allosteric MEK Inhibitor, CH5126766, That Suppresses Feedback Reactivation of RAF Activity
2023 · Nobuya Ishii, Naoki Harada, et al.
Supplementary Figure S3 from Enhanced Inhibition of ERK Signaling by a Novel Allosteric MEK Inhibitor, CH5126766, That Suppresses Feedback Reactivation of RAF Activity
2023 · Nobuya Ishii, Naoki Harada, et al.
Supplementary Table S1 from Enhanced Inhibition of ERK Signaling by a Novel Allosteric MEK Inhibitor, CH5126766, That Suppresses Feedback Reactivation of RAF Activity
2023 · Nobuya Ishii, Naoki Harada, et al.
PDF
Supplementary Materials and Methods from Enhanced Inhibition of ERK Signaling by a Novel Allosteric MEK Inhibitor, CH5126766, That Suppresses Feedback Reactivation of RAF Activity
2023 · Nobuya Ishii, Naoki Harada, et al.
PDF
Works count: 35
Citation count: 589
H-index: 12
I10-index: 12
Year
Topic
Type